A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras

Drugs and Aging

Volumn 33, Issue 6, 2016, Pages 427-436

  Brown, Joshua D ^a   Shewale, Anand R ^b   Dherange, Parinita ^c   Talbert, Jeffery C ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c Sarver Heart Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COHORT ANALYSIS; COMORBIDITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON VALVULAR ATRIAL FIBRILLATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; CHEMICALLY INDUCED; DRUG UTILIZATION; HEMORRHAGE; ORAL DRUG ADMINISTRATION; RISK; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; STROKE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; COMORBIDITY; DRUG UTILIZATION; FEMALE; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; RISK; STROKE; WARFARIN;

EID: 84966359538     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-016-0369-y     Document Type: Article

References (52)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.
2. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274(5):461–8.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987;147(9):1561–4.
4. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin: fourth edition. Br J Haematol. 2011;154(3):311–24.
5. Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med. 2007;39(5):371–91.
6. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.
7. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S–75S.
8. Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. Am J Med. 2014;127(11):1075, 82.e1.
9. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.
10. Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. 2012;157(11):796–807.
11. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5(4):480–6.
12. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):615–21.
13. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol. 2015;115(8):1095–101.
14. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–47. doi:10.1093/eurheartj/ehs253.
15. Dave D, Saffer H. The impact of direct-to-consumer advertising on pharmaceutical prices and demand. 2010. Report No.: NBER Working Paper No. 15969.
16. David G, Markowitz S. Side effects of competition: the role of advertising and promotion in pharmaceutical markets. 2011. Report No.: NBER Working Paper No 17162.
17. Shewale A, Johnson J, Li C, Nelsen D, Martin B. Variation in anticoagulant recommendations by the guidelines and decision tools among patients with atrial fibrillation. Healthcare. 2015;3(1):130–45.
18. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.
19. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.
20. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.
21. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234–40.
22. Pauly NJ, Brown JD. Prevalence of low-cost generic program use in a nationally representative cohort of privately insured adults. J Manag Care Spec Pharm. 2015;21(12):1162–70.
23. Lauffenburger JC, Balasubramanian A, Farley JF, Critchlow CW, O’Malley CD, Roth MT, et al. Completeness of prescription information in US commercial claims databases. Pharmacoepidemiol Drug Saf. 2013;22(8):899–906.
24. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke. 2006;37(8):1969–74.
25. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, et al. Antithrombotic therapy for VTE disease. Chest. 2016;149(2):315–52.
26. Ng KH, Shestakovska O, Connolly SJ, Eikelboom JW, Avezum A, Diaz R, et al. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing. 2016;45(1):77–83.
27. Zhou M, Chang HY, Segal JB, Alexander GC, Singh S. Adherence to a novel oral anticoagulant among patients with atrial fibrillation. J Manag Care Spec Pharm. 2015;21(11):1054–62.
28. Luger S, Hohmann C, Niemann D, Kraft P, Gunreben I, Neumann-Haefelin T, et al. Adherence to oral anticoagulant therapy in secondary stroke prevention—impact of the novel oral anticoagulants. Patient Prefer Adherence. 2015;23(9):1695–705.
29. Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Idarucizumab: the antidote for reversal of dabigatran. Circulation. 2015;132(25):2412–22.
30. Rosanio S, Keylani AM, D’Agostino DC, DeLaughter CM, Vitarelli A. Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. Int J Cardiol. 2014;174(3):471–83.
31. Garber JL, Willenborg KL, Rose AE. Analysis of anticoagulant prescribing in non-valvular atrial fibrillation and development of a clinical tool for guiding anticoagulant selection. J Thromb Thrombolysis. 2015;40(2):248–54.
32. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677–85.
33. Formiga F, Fort I, Reig L, Robles MJ, Espinosa MC, Rodriguez D. Atrial fibrillation in elderly patients with dementia. Gerontology. 2009;55(2):202–4.
34. Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother. 2009;7(3):159–66.
35. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689–96.
36. Spyropoulos AC, Goldenberg NA, Kessler CM, Kittelson J, Schulman S, Turpie AG, et al. Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm? J Thromb Haemost. 2012;10(12):2621–4.
37. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–6. doi:10.1200/JCO.2014.59.7351.
38. Frere C, Debourdeau P, Hij A, Cajfinger F, Onan MN, Panicot-Dubois L, et al. Therapy for cancer-related thromboembolism. Semin Oncol. 2014;41(3):319–38.
39. van der Hulle T, den Exter PL, Kooiman J, van der Hoeven JJ, Huisman MV, Klok FA. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost. 2014;12(7):1116–20.
40. Limone BL, Baker WL, Kluger J, Coleman CI. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One. 2013;8(4):e62183.
41. Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: do we anticoagulate CHADS2 or CHA2DS2-VASc >/=1, or higher? Thromb Haemost. 2015;113(6):1165–9.
42. Nicholls SG, Brehaut JC, Arim RG, Carroll K, Perez R, Shojania KG, et al. Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians. Thromb J. 2014;12:13,9560-12-13 (eCollection 2014).
43. van Doorn S, Hartman-Weide F, Geersing GJ, Oudega R, Hoes AW, Rutten FH. Reasons for non-adherence to practice guidelines on stroke prevention in patients with atrial fibrillation: a cross-sectional study in primary care. Int J Cardiol. 2015;187:525–6.
44. Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med. 2006;119(7):607–15.
45. Lewis WR, Piccini JP, Turakhia MP, Curtis AB, Fang M, Suter RE, et al. Get with the guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2014;7(5):770–7.
46. Get With The Guidelines—AFIB [Internet]. http://www.heart.org/HEARTORG/HealthcareResearch/GetWithTheGuidelines/GetWithTheGuidelines-AFIB/Get-With-The-Guidelines-AFIB_UCM_448881_SubHomePage.jsp. Accessed 30 Jan 2016.
47. Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm. 2013;19(4):302–16.
48. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323–37.
49. Zhan C, Miller MR. Administrative data based patient safety research: a critical review. Qual Saf Health Care. 2003;12(Suppl 2):ii58–63.
50. Ntaios G, Lip GY, Makaritsis K, Papavasileiou V, Vemmou A, Koroboki E, et al. CHADS(2), CHA(2)S(2)DS(2)-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology. 2013;80(11):1009–17.
51. Jacobs V, May HT, Bair TL, Crandall BG, Cutler M, Day JD, et al. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. Heart Rhythm. 2015;12(4):681–6.
52. Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62(23):2199–204.